Why did NXTC's EPS remain flat in 2024?

NextCure's EPS remained flat in 2024 due to a combination of factors:

1. **Consistent Financial Performance**: NextCure's EPS has been negative and relatively stable throughout 2024, with figures of -$0.61 for Q1, -$0.55 for Q2, and -$1.99 for Q4. This consistency suggests that the company's financial performance has not significantly improved or worsened over the year.
2. **No Revenue Recognition**: NextCure has not reported any revenue for several quarters, including Q1 2024 and Q2 2024. The lack of revenue recognition contributes to the negative EPS figures, as the company's income is not offset by any sales.
3. **Higher Costs**: Despite the lack of revenue, NextCure's research and development expenses have remained high, with figures of $11.4 million for Q1 2024 and $11.6 million for Q1 2023. These higher costs, coupled with the lack of revenue, have likely contributed to the company's financial losses and flat EPS.
4. **Cash Management**: NextCure's cash position has decreased from $108.3 million as of December 31, 2023, to $96.0 million as of March 31, 2024. This decrease in cash is primarily due to cash used to fund operations, which has put pressure on the company's financial stability and has contributed to the flat EPS trend.

In conclusion, NextCure's flat EPS in 2024 can be attributed to a combination of consistent financial performance, lack of revenue recognition, higher costs, and cash management challenges.